The effects of osteoclast activating factor (OAF) released by normal human peripheral blood leukocytes cultured with phytohemagglutinin have been examined in organ culture. Like parathyroid hormone (PTH), OAF causes a rapid increased in the release of previously incorporated 45Ca from fetal rat bone after brief or continuous exposure; the bones also lose stable calcium and collagen content. The resorption response to OAF also resembles that of PTH in having a steep dose response curve and being only transiently inhibited by calcitonin and partially inhibited by increasing medium phosphate concentration. OAFstimulated resorption was inhibited more effectively by cortisol than was PTH stimulation. The response to maximally effective doses of OAF was not enhanced by PTH or prostaglandin E2, but submaximal doses gave additive effects. Both OAF and PTH inhibit collagen synthesis in fetal rat calvaria at the concentrations that stimulate bone resorption. A B S T R A C T The effects of osteoclast activating factor (OAF) released by normal human peripheral blood leukocytes cultured with phytohemagglutinin have been examined in organ culture. Like parathyroid hormone (PTH), OAF causes a rapid increase in the release of previously incorporated 'PCa from fetal rat bone after brief or continuous exposure; the bones also lose stable calcium and collagen content. The resorption response to OAF also resembles that of PTH in having a steep dose response curve and being only transiently inhibited by calcitonin and partially inhibited by increasing medium phosphate concentration. OAF-stimulated resorption was inhibited more effectively by cortisol than was PTH stimulation. The response to maximally effective doses of OAF was not enhanced by PTH or prostaglandin E2, but submaximal doses gave additive effects. Both OAF and PTH inhibit collagen synthesis in fetal rat calvaria at the concentrations that stimulate bone resorption.
INTRODUCTION
Osteoclast activating factor (OAF)' has been found in the supernatant fluid of cultures of normal human peripheral blood leukocytes that have been activated by 1Abbreviations used in this paper: BGJ, a chemically defined medium developed by Biggers, Gwatkin, and Heyner (1) ; OAF, osteoclast activating factor; 25-OH Ds, 25-hyan antigen or plant mitogen such as phytohemagglutinin (PHA) (2) . OAF is detected by its ability to stimulate resorption of fetal rat bone in organ culture. Chemically it is a protein-containing macromolecule which can be differentiated from other known stimulators of bone resorption such as parathyroid hormone (PTH), active metabolites of vitamin D, and prostaglandins (3) . In the present studies OAF has been compared with these agents for its effects on bone resorption and bone collagen synthesis in culture. OAF and PTH had similar effects in vitro, except that OAF appeared more susceptible to inhibition by cortisol.
METHODS
OAF was obtained from supernates of cultures of normal human leukocytes activated with PHA as described elsewhere (2, 3). Supernates were harvested at 14 days. The following preparations were used for biological studies: (a) crude OAF, the supernate was diluted with BGJ (chemically defined medium developed by Biggers, Gwatkin, and Heyner [1] ) and assayed either directly or after concentration by ultrafiltration on an Amicon PM10 membrane (Amicon Corp., Lexington, Mass.) with a nominal mol wt cutoff of 10,000. (b) Fraction IV OAF was obtained by chromatography of concentrated crude OAF on Sephadex G-100 (2.5 X 40 cm, 0.02 M phosphate in 0.15 M NaCl at pH 7.2) and was that fraction eluting between the molecular weight markers, chymotrypsinogen (25,000 daltons), and ribonuclease A (13,700 daltons). Fraction Bone resorption assays. Bone resorption was measured in organ cultures of the shafts of the radius and ulna of 19-day fetal rats (4) . The bones were labeled by injection of the mother with 0.2-0.4 mCi of 45Ca 1 day before sacrifice. Bones were cultured in BGJ supplemented with 1 or 4 mg/ml of bovine serum albumin Fraction V (BSA, Armour Pharmaceutical Co.). After 18-24 h of preculture bones were transferred to paired treated and control cultures for an additional 48 h, and 45Ca was measured in the medium by liquid scintillation counting. In other experiments the bones were not paired and the percentage of "5Ca released was calculated. In a few experiments, stable calcium content of the bone was measured by atomic absorption spectrophotometry and ccllagen content by analysis of hydroxyproline (5) .
Bone collagen synthesis studies. Effects on bone collagen synthesis were assessed using short-term cultures of half calvaria (the central thin portions of the frontal and parietal bone) from 21-day fetal rats. Two to four calvaria were incubated in 5 ml of BGJ with BSA for 24 h at 370C in a humidified atmosphere of 5%o CO2 in air. The cultures were placed on a rocking platform (Belco Glass Inc., Vineland, N. J.) which tipped them to an angle of 150 at 6 cycle/min. During the last 2 h of incubation 5 AtCi/ml of [2,3-3H] proline (New England Nuclear, Boston, Mass., 30 Ci/mole) was added to the medium. At the end of culture the bones were either dialyzed exhaustively against 0.5 M acetic acid or washed in 5% trichloroacetic acid, acetone, and ether, and weighed on a Cahn electrobalance (Cahn Div., Ventron Instruments Corp., Cerritos, Calif.). The weighed bones were homogenized in 0.5 M acetic acid, and aliquots were analyzed for radioactivity in collagenase digestible and noncollagen protein using purified bacterial collagenase (6) . The relative proportion of collagen to total protein synthesis (percent collagen synthesized) was calculated using a factor of 5.4 to correct for the greater abundance of proline in collagen than in noncollagen protein.
RESULTS
Supernates of normal human peripheral blood leukocytes cultured with PHA always contained bone-resorbing activity. The amount of crude OAF that produced maximum bone resorption ranged from a twofold con- 'Ca release below control values. More purified preparations sometimes also showed this decrease in effect but more often showed a plateau at the maximal response ( Fig. 1) . The steep portion of the dose-response curve was similar for all OAF preparations and for PTH. The mean change in T/C ratio (treated/control) for the twofold dilution representing the steepest portion of the dose-response curve for crude OAF was 0.61± 0.06 (n = 14). For Fraction IV OAF the mean change was 0.62±0.04 (n = 11) and for DEAE OAF 0.62+ 0.10 (n = 6). The change in T/C ratios for twofold dilution of PTH was 0.65+0.09 (n = 7).
OAF caused loss of stable calcium and of collagen from the bone. For example in one experiment maximally effective concentrations of OAF decreased stable bone calcium content by 46+4% (n = 4) and collagen content by 51+±15% compared with untreated control. The time-course for increasing 'Ca release after OAF and PTH were also similar, and continued resorption was observed after brief exposure to either agent (Fig. 2) .
At supramaximal concentration, PGE2, 1,25-(OH) 2DI
and OAF could all induce prolonged resorption after brief exposure, but OAF showed a greater effect than PGE2 (Table I) used.
* T/C ratio. tSignificantly greater than 1.0 (P < 0.05).
doses of PTH or PGE2 did not significantly increase 'Ca release further. As observed previously with PTH (4), the effect of OAF on percent of total bone 'Ca released could be reduced by increasing the phosphate concentration in the medium from 1 to 3 mM; however, 'Ca release from control cultures was also reduced so that T/C ratios were unchanged. Pretreatment of the bone with 3 mM phosphate did not alter the subsequent response to OAF (Table III) . Calcitonin blocked the initial effect of OAF on 'Ca release; but, as observed previously with PTH and 25-hydroxy-vitamin Da (25-OHDs) (7) , 'Ca release increased during continued adminstration of supramaximal doses of SCT and OAF (Fig. 3) . OAF was more sensitive to inhibition by cortisol than PTH (Ta- (Table V) .
Bone collagen synthesis assays. After 24-h culture of fetal rat calvaria with high concentration of either PTH or OAF, the incorporation of a 2-h pulse of ['H]-proline into collagenase-digestible protein was inhibited by more than 50% (Table VI) . The incorporation of proline into noncollagen protein was less affected, so that collagen synthesis represented a smaller percentage of newly synthesized protein. This occurred with both crude and purified OAF preparations. In this system PTH and OAF were more effective both as stimulators of "Ca release and inhibitors of collagen synthesis than 1,25-(OH)2Ds (Table VI, Values are means ±SE for four cultures.
* T/C ratio.
1 Significantly greater than 1.0, P < 0.01.
tion of collagen synthesis was observed at a low concentration, whereas a higher concentration also inhibited noncollagen protein synthesis (data not shown).
DISCUSSION
The present studies indicate that the bone resorbing factor secreted by human leukocytes, which we have named OAF, acts much like PTH in organ cultures of fetal rat bone. Crude and partially purified preparations of OAF gave similar effects except that the cruder preparations more often showed loss of effect at supramaximal concentrations. This could have been due to toxic contaminants since at high concentrations certain OAF preparations inhibited 'Ca release below controls.
The ascending portions of the dose-response curves were steep and had similar slopes at all steps of purification. The similarity of slope, together with the chromatographic results (2) , suggest that the stimulation of bone resorption by OAF could be ascribed to the effects of a single material. The slope of the dose-response curve for PTH was not significantly different from that for OAF while that for vitamin D metabolites is less steep and for PGE2 much less steep (8) . The first three agents all act rapidly and have similar effects on removal of mineral and matrix.
The interactions of OAF, PTH, and PGE2 were examined largely because all three agents are potential mediators of neoplastic and inflammatory bone loss. Effects were additive at low concentrations, but PTH and PGE2 did not increase resorption further in the presence of high concentrations of OAF. This probably reflects the limited capacity of the tissue to respond and need not indicate a common receptor or mechanism of action. In preliminary studies treatment with OAF, unlike PTH and PGE2, has not increased cyclic 3',5'-adenosine monophosphate concentrations in cultured bone (L. G. Raisz, and W. A. Peck, unpublished observations).
OAF resembles PTH in being less effective at high medium phosphate concentrations but still stimulates reOsteoclast Activating Factor from Human Leukocytes on Bone Metabolism sorption in high phosphate medium. In fact, OAF activity was first detected using medium RPMI 1640 which has a phosphate concentration over 5 mM (2) . OAF showed the characteristic initial inhibition by calcitonin followed by escape (7) . Failure to inhibit OAF or PTH with indomethacin suggests that prostaglandin synthesis does not mediatte the resorptive effects of these two agents.
The concentration of indomethacin used has been shown to inhibit complement dependent stimulation of prostaglandin synthesis and bone resorption (9) The rough reciprocal relation between inhibition of osteoblastic collagen synthesis and stimulation of osteoclastic bone resorption in culture need not indicate any connection between the two phenomena at the cellular level. Moreover, in the case of OAF, it is not certain that these two effects are mediated by the same substance, although the persistence of both effects through two stages of purification supports this possibility. DEAE-OAF is not pure and may still contain toxic contaminants. This seems unlikely since OAF inhibited collagen labeling at concentrations which did not affect noncollagen protein labeling. These results do not bear on the specificity of OAF for bone. We are currently testing whether these preparations influence metabolism of other tissues.
Despite its powerful effects on bone in vitro, we have been unable to increase serum calcium concentrations by injection of large quantities of OAF in intact or thyroparathyroidectomized rats (Raisz, unpublished observations) . A similar dissociation between in vitro and in vivo effects has been observed with prostaglandins (12) . This could have been due to rapid inactivation of OAF in the circulation which prevented its reaching bone in sufficient concentrations. Direct measurements of OAF in blood will be required to assess this possibility. There is now some evidence that OAF production may be clinically important. OAF-like factors have been found in the supernates of cultured lymphoid cell lines as well as short-term cultures of bone marrow cells aspirated from patients with myeloma (8, 13). OAF could also be released in chronic inflammation by activated lymphocytes (14) . The effects of OAF we observed in vitro are consistent with the nature of the bone lesions in periodontal disease and in myeloma. In both disorders, bone destruction is osteoclastic, local, and not regularly associated with an increase in bone formation. It is even more difficult to 412 ascribe a physiologic function to OAF. If bone marrow lymphocytes produced OAF during their proliferation, this might enhance endosteal bone resorption and facilitate the rapid development of the medullary cavity. If so, some forms of osteopetrosis in animals and man in which bone marrow formation and bone resorption are both decreased and medullary bone formation appears to be excessive could be related to deficient OAF production.
